• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Healthcare·PANCHSHEEL.BO
Share

Panchsheel Organics Limited Stocks

₹ 118.1Last Updated 27.07.2026

Issuer Rating

4/7
Performance

Favourable

Risk

Considerable

Recommendation

Hold

Market Cap

₹ 16.10M

₹ 118.1
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Founded on August 2, 1989, Panchsheel Organics Ltd. is an Indian enterprise based in Mumbai, specializing in the production of pharmaceutical and medicinal chemical goods. The company's diverse offerings include anti-cancer medications (spanning oncology and therapeutics), biosimilar products, nutraceuticals, and a variety of fitness and wellness items. Additionally, it provides steroids and hormones, veterinary medicines, over-the-counter (OTC) products, and active pharmaceutical ingredients (APIs) with their intermediates, supported by its dedicated development and testing laboratory.

Company Valuation

Undervalued
6/7

Based on key historical and expected multiples, the stock is undervalued relative to its peers. Specifically, the stock is 'cheap' on P/E, neutral on EV/EBITD.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

29.07.2026 22:23

"It's a Matter of Lost Trust": Chipmakers Lost More Than $1 Trillion in Market Capitalization in Two Days

29.07.2026 22:06

Novo Will Sue Investors Over the Results of a Study on a Weight-Loss Drug

29.07.2026 21:47

Insiders in the AI boom were among the biggest sellers on the eve of the chipmakers' crash

29.07.2026 20:35

Noble is first on Wall St. to cover Beasley Broadcast Group, seeing almost 50% upside

29.07.2026 19:56

"The Focus Is Back on Iran": U.S. Stocks See a Sell-Off Ahead of the Fed's Decision

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026